CP 424174

CAS No. 210825-31-3

CP 424174( —— )

Catalog No. M22980 CAS No. 210825-31-3

CP 424174 is an inhibitor of IL-1β post-translational processing with IC50 of 210 nM. Inhibits the formation of mature IL-1β. Indirectly inhibits NLRP3. Active in vivo and orally bioavailable.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 64 In Stock
5MG 90 In Stock
10MG 137 In Stock
25MG 246 In Stock
50MG 368 In Stock
100MG 536 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CP 424174
  • Note
    Research use only, not for human use.
  • Brief Description
    CP 424174 is an inhibitor of IL-1β post-translational processing with IC50 of 210 nM. Inhibits the formation of mature IL-1β. Indirectly inhibits NLRP3. Active in vivo and orally bioavailable.
  • Description
    CP 424174 is an inhibitor of IL-1β post-translational processing with IC50 of 210 nM. Inhibits the formation of mature IL-1β. Indirectly inhibits NLRP3. Active in vivo and orally bioavailable.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    IL Receptor
  • Recptor
    IL-1β
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    210825-31-3
  • Formula Weight
    452.99
  • Molecular Formula
    C22H29ClN2O4S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (275.94 mM)
  • SMILES
    O=S(C1=CC=CC(C(C)(O)C)=C1)(NC(NC2=C(C(C)C)C=C(Cl)C=C2C(C)C)=O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Perregaux D G , Mcniff P , Laliberte R , et al. Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors.[J]. Journal of Pharmacology & Experimental Therapeutics, 2001, 299(1):187.
molnova catalog
related products
  • Bermekimab

    Bermekimab (MABp1) is a humanized monoclonal antibody against interleukin-1α (IL-1α).Bermekimab has potential anti-inflammatory activity to prevent skin inflammation.

  • Daclizumab

    Daclizumab (Zenapax) is a humanized monoclonal antibody that specifically inhibits the alpha subunit of IL-2R-HA.

  • Procyanidin A2

    Procyanidin A2 is a potential precursor of 5-(3',4'-dihydroxyphenyl)-γ-valerolactone, exhibits antioxidant, anti-inflammary, anti-hyperglycemia, and anti-type 2 diabetes activities.